Zymeworks (ZYME) Cash & Equivalents (2021 - 2026)

Zymeworks has disclosed Cash & Equivalents across 6 years of filings, most recently posting $244.3 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $244.3 million, up 220.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $244.3 million (up 220.56% YoY), and the FY2025 annual result was $41.2 million, down 37.74% from the prior year.
• Cash & Equivalents came in at $244.3 million for Q1 2026 at Zymeworks, up from $41.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $400.9 million in Q4 2022 to a low of $41.2 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $98.3 million (2025), against an average of $131.4 million.
• Across the five-year window, Cash & Equivalents sank 60.7% in 2023 and surged 220.56% in 2026, its largest moves.
• Zymeworks' Cash & Equivalents stood at $400.9 million in 2022, then tumbled by 60.7% to $157.6 million in 2023, then tumbled by 58.05% to $66.1 million in 2024, then plunged by 37.74% to $41.2 million in 2025, then soared by 493.54% to $244.3 million in 2026.
• The last three Cash & Equivalents figures came in at $244.3 million (Q1 2026), $41.2 million (Q4 2025), and $64.8 million (Q3 2025), per Business Quant data.